Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials

@article{Rothwell2011EffectOD,
  title={Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials},
  author={Peter M. Rothwell and F. Gerald R. Fowkes and Jill J.F. Belch and Hisao Ogawa and Charles P. Warlow and Tom W Meade},
  journal={The Lancet},
  year={2011},
  volume={377},
  pages={31-41}
}
View on Elsevier
gwern.net
1,333 Citations
Highly Influential Citations
67
Background Citations
471
Methods Citations
42
Results Citations
47

Figures and Tables from this paper

1,333 Citations

Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials

Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials

Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials.

Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials

Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial

Will an aspirin a day help keep fatal cancer away?

Daily aspirin use and cancer mortality in a large US cohort.

TLDR
Results are consistent with an association between recent daily aspirin use and modestly lower cancer mortality but suggest that any reduction in cancer mortality may be smaller than that observed with long-term aspirin use in the pooled trial analysis.

Low-dose aspirin and cancer mortality: a meta-analysis of randomized trials.

Aspirin in prevention of sporadic colorectal cancer: current clinical evidence and overall balance of risks and benefits.

  • P. Rothwell
  • Medicine
    Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer
  • 2013
TLDR
Evidence from randomised trials of the effectiveness of aspirin for chemoprevention of colorectal cancer has increased substantially in recent years, and recent evidence shows that the risk of major bleeding on aspirin diminishes with prolonged use, suggesting that the balance of risk and benefit favours the use of daily aspirin in primary prevention of colOREctal and other cancers.

Alternate-Day, Low-Dose Aspirin and Cancer Risk: Long-Term Observational Follow-up of a Randomized Trial

TLDR
Long-term use of alternate-day, low-dose aspirin may reduce risk for colorectal cancer in healthy women and posttrial ascertainment bias cannot be ruled out.
...

References

SHOWING 1-10 OF 49 REFERENCES

Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials

Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies

Low-Dose Aspirin in the Primary Prevention of Cancer: The Women’s Health Study: A Randomized Controlled Trial

TLDR
Results from this large-scale, long-term trial suggest that alternate day use of low-dose aspirin for an average 10 years of treatment does not lower risk of total, breast, colorectal, or other site-specific cancers.

Eff ect of aspirin on long-term risk of colorectal cancer : consistent evidence from randomised and observational studies

TLDR
Aspirin has been shown to reduce experimentally-induced colonic malignancies in animals, and some observational studies have reported a reduced incidence of colorectal cancers in regular users of aspirin, although there is substantial heterogeneity in apparent heterogeneity between studies.

Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.

Aspirin for the primary prevention of vascular events?

Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials

Cost-Effectiveness of Aspirin Treatment in the Primary Prevention of Cardiovascular Disease Events in Subgroups Based on Age, Gender, and Varying Cardiovascular Risk

TLDR
Aspirin treatment for primary prevention is cost-effective for men with a 10-year cardiovascular disease risk of >10% and for women with a risk of>15%, which occurs much later in life for women than men.

Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial.

TLDR
In this study of patients with type 2 diabetes, low-dose aspirin as primary prevention did not reduce the risk of cardiovascular events.

Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials.

TLDR
Aspirin is effective for the prevention of colorectal adenomas in individuals with a history of these lesions and no statistically significant effect modification for any of the baseline factors studied.